What looks promising
A narrow absorption-oriented intended-use lane can be discussed using public K252005 and HEB records as preparation clues. This gives the founder a credible starting point for a qualified review call.
Report map
- Executive answer
- Method and decision boundaries
- Comparator and competitive map
- Same / different analysis
- Market size and scenario math
- Regulatory and consultant prep
- Revenue-readiness bridge
- Appendix and source ledger
How to read this sample
This sample borrows the structure of professional market-entry and competitive-intelligence reports: consistent comparison criteria, action-oriented section titles, clear caveats, and source-backed tables. It does not copy any third-party template content.
1. Executive answer: the public analog is useful, but the sales story is still the biggest open question.
What still blocks confidence
The report cannot know the customer's exact claims, materials, use duration, pricing, channel, and buyer reason from public records alone. These are the inputs that determine whether the pack becomes actionable.
Regulatory clueStrong
Useful review lane, not a final answer.
Comparator depthGood
Two public device records plus adjacent category context.
Buyer reasonWeak
Needs customer validation before sales language.
Claim drift riskHigh
Sales and distributor language must be controlled.
| Decision question | Current answer | Why it matters | Owner |
|---|---|---|---|
| Can we explain the product in one narrow, supportable sentence? | Partly | The public analog gives an absorption-oriented wording lane, but the customer's exact intended use, label, website, and sales language must be confirmed. | RA/QA + founder |
| Do we know what makes the buyer act now? | Not yet | The likely buyer reason is a repeatable post-intercourse routine, but pricing, use frequency, consumer willingness, and channel conversion remain unvalidated. | Founder + commercial lead |
| Do public comparators help frame the first review call? | Yes, as clues | K252005 and K241064 give a useful same/different discussion map. They do not prove product-code fit or predicate suitability for a new product. | Consultant + RA/QA |
| Can this become revenue-ready after market entry? | Yes, if boundary is controlled | The same pack can become the base for sales handouts, distributor scripts, claim-boundary training, and buyer-reason testing. | Founder + sales lead |
2. Method and decision boundaries: this is a preparation packet, not a final regulatory conclusion.
Professional reports are valuable when they show how the analysis was constructed. This section protects trust: it tells the reader what was checked, what was assumed, and where judgment remains with the customer and qualified reviewers.
| Workstream | What was reviewed | What the report can say | What it must not say |
|---|---|---|---|
| Public FDA record review | K252005, K241064, product-code and regulation records | Identify review clues and open questions | Declare final classification, clearance path, predicate suitability, safety, or effectiveness |
| Market and category review | Public category estimates, launch-channel clues, target-population data sources | Build scenario math and validation questions | Claim a reliable forecast or guaranteed demand |
| Competitive positioning | Similar/different product facts and adjacent alternatives | Frame buyer-reason hypotheses and risks | Promise sales conversion or make unsupported claims |
| Consultant preparation | Questions, evidence gaps, source ledger, decision table | Help the customer run a better professional review call | Replace qualified regulatory, legal, clinical, or quality review |
3. Comparator and competitive map: the customer should see both the regulatory analog and the commercial alternatives.
Professional competitor-analysis templates emphasize consistent dimensions across every competitor. The table below keeps each product or alternative on the same rows so the reader can compare quickly.
| Comparable product / group | Company or source | Public positioning | Relevant facts | Why it matters | Limitations |
|---|---|---|---|---|---|
| K252005 Livi Device | LiviWell Inc. | Post-intercourse absorption of semen or other vaginal discharge | OTC, single-use, non-sterile, intravaginal absorbent with applicator-like use | Closest public analog for a Livi-like concept | Do not imply the customer has the same clearance or evidence. |
| K241064 Unscented Tampon | Shandong Intco Hygiene Products Co., Ltd. | Menstrual or other vaginal discharge absorption | Traditional unscented tampon, single-use, non-sterile | Useful product-code and predicate context named in K252005 | Different commercial job and use moment from post-intercourse positioning. |
| Adjacent intimate-care routines | Multiple brands / channels | Freshness, cleanup, comfort, liners, wipes, hygiene routines | Often consumer products rather than direct device predicates | Competes for habit, shelf space, attention, and trust | May create claim drift into odor, pH, infection, wellness, or therapeutic territory. |
4. Same / different analysis: the report should show where similarity is strong and where it breaks.
| Dimension | What appears similar | What may be different | What to do next |
|---|---|---|---|
| Intended use | Likely similar if customer stays within absorption of semen / other vaginal discharge after intercourse | Any pregnancy, sexually transmitted infection (STI), fertility, infection, odor, or treatment language changes the review question | Use customer exact wording before consultant call. |
| Technology | Intravaginal absorbent concept may be comparable at a high level | Material, geometry, string, applicator, wear time, absorbency, shedding, and packaging still need proof | Build a design-and-testing table, not a generic feature list. |
| User experience | Familiarity may exist for users comfortable with tampon-like insertion | The use moment is not menstruation; buyer reason and hesitation will differ | Research the buyer's real post-intercourse routine and objections. |
| Commercial story | Can be positioned around confidence, routine, and convenience if supported | Sales can easily overclaim into clinical or wellness outcomes | Separate approved words, review-needed words, and forbidden words. |
Do not sell the feature first
If sales leads with technical absorption language, it can drift into claims the company has not reviewed. The better first question is what moment makes the buyer care.
Do not hide the boundary
A visible do-not-say list is not a weakness. It makes distributors more useful because they know how to sell without inventing claims.
Make every claim traceable
Any phrase used in a handout, website, ad, distributor script, or customer-support answer should map back to a reviewed source or customer-approved fact.
5. Market size and scenario math: use public numbers as inputs, then force the customer to replace the assumptions.
| Input type | Market or data point | Public value | Source type | Limitation |
|---|---|---|---|---|
| Broad category context | North America feminine hygiene products | USD 8.76B in 2024 | Third-party public summary | Frames category size only; not a revenue forecast. |
| Closer category proxy | Global tampon market | USD 6.6B in 2024 | Third-party public summary | Useful habit proxy, but not post-intercourse demand. |
| Launch-channel signal | Online first, retail later | Public LiviWell announcement | Trade/public announcement | Supports channel planning; does not prove conversion. |
| Population data input | U.S. age/sex population table | Dataset available | U.S. Census | Must be filtered by target age, adoption, use frequency, price, and channel. |
| Scenario | Assumption | Estimated annual retail value | Simple math | What must be true |
|---|---|---|---|---|
| Founder sanity check | 0.05% of broad North America category | Approx. USD 4.4M annual retail value | 8.76B x 0.05% | Use case is real but remains a small niche. |
| Focused direct-to-consumer wedge | 0.25% of broad North America category | Approx. USD 21.9M annual retail value | 8.76B x 0.25% | Clear buyer reason, repeat use, online conversion, and acceptable price. |
| Strong category wedge | 0.5% of broad North America category | Approx. USD 43.8M annual retail value | 8.76B x 0.5% | Retail expansion, repeat purchase, distributor discipline, and claim control. |
| Tampon-adjacent proxy | 0.1% to 1.0% of global tampon category | Approx. USD 6.6M to USD 66M annual retail value | 6.6B x 0.1% to 1.0% | Only a proxy. Replace with U.S. target-user and price-frequency math. |
This is the section that makes the report feel like a business tool, not only a regulatory checklist. The customer can challenge the assumptions, replace the numbers, and immediately see what must be true for the market to be worth entering.
6. Regulatory and consultant prep: the paid pack should reduce the first consultant call from discovery to review.
| Review topic | Bring this to the call | Ask this question | Boundary |
|---|---|---|---|
| Intended use and claims | Exact label, website, ad, and distributor wording | Ask whether wording changes route, evidence, or review burden. | Do not ask for a yes/no clearance prediction. |
| Candidate lane | HEB / 21 CFR 884.5470 public clue and same/different map | Ask what facts would make this lane weak or wrong. | Treat product-code fit as review work. |
| Evidence burden | Materials, duration, non-sterile/single-use status, bench tests, comprehension testing | Ask what evidence is missing before submission planning. | Do not assume K252005 evidence transfers. |
| Commercial boundary | Buyer reason, do-not-say list, one-page handout | Ask what claims require review before sales/distributor use. | Keep revenue language inside reviewed boundaries. |
7. Revenue-readiness bridge: the pack should prepare the sales system before clearance is the only focus.
| Future asset | What this report contributes | What customer must confirm |
|---|---|---|
| One-page customer handout | Feature facts, buyer-reason hypotheses, and claim-boundary risks | Final reviewed claims and customer-approved wording |
| Sales/distributor script | Do-not-say boundaries and likely buyer objections | Actual sales process, channel, objections, and close criteria |
| Training room scenarios | Customer type, first-touch questions, buyer reason, overclaim risks | Target buyer roles and approved practice cases |
| Customer-support agent | Source ledger and safe answer boundaries | Instructions, troubleshooting data, complaint routing, and support workflows |
8. Recommended paid-pack deliverable structure: sell a packet that different teams can actually use.
| Module | Primary audience | Concrete use |
|---|---|---|
| 1. Executive decision brief | Founder / investor | One-page view of what seems promising, what is unknown, and what must be reviewed next. |
| 2. Regulatory review map | Regulatory Affairs / Quality Assurance (RA/QA) | Candidate review lenses, evidence gaps, source-backed comparator clues, and questions for qualified review. |
| 3. Comparator and market map | Founder / product / marketing | Side-by-side product context, similar/different analysis, market proxies, and commercial implications. |
| 4. Consultant call packet | External consultant | Agenda, source ledger, exact questions, and decision table so the call starts from evidence instead of generic discovery. |
| 5. Revenue-readiness bridge | Sales / distributor owner | Buyer reason hypotheses, claim-boundary risks, early handout needs, and training-room inputs. |
Appendix A. Source ledger
| Source ID | Source | Supports |
|---|---|---|
| fda-k252005-db | FDA 510(k) Premarket Notification Database - K252005 | K252005 metadata: Livi Device, applicant, product code HEB, regulation 21 CFR 884.5470, decision date, review type, and panel. |
| fda-k252005-summary | FDA 510(k) Summary PDF - K252005 Livi Device | Livi Device description, indications for use, predicate, design differences, and non-clinical / labeling-comprehension testing summary. |
| fda-heb-classification | FDA Product Classification - HEB | Product code HEB, Class II, regulation 21 CFR 884.5470, submission type 510(k), and product-code definition. |
| ecfr-884-5470 | 21 CFR 884.5470 - Unscented menstrual tampon | Regulatory identification and Class II classification language for unscented menstrual tampon devices. |
| fda-k241064-db | FDA 510(k) Premarket Notification Database - K241064 | Predicate device metadata used by K252005: Unscented Tampon, applicant, product code HEB, decision date, and review type. |
| fda-k241064-summary | FDA 510(k) Summary PDF - K241064 Unscented Tampon | Predicate indications, materials, design, absorbency, single-use and non-sterile characteristics. |
| fda-fy2026-fees-current | FDA MDUFA FY2026 Fees | FY2026 FDA fees including 510(k), 513(g), De Novo, PMA, and establishment registration fees. |
| fda-user-fees-current | FDA Medical Device User Fees | Payment timing, small-business decision number, and FDA Form 3601 cover-sheet requirement. |
| liviwell-commercial-availability | LiviWell public commercial announcement via BioSpace | Public Livi commercial framing: post-intercourse fluid absorption, soft polyurethane foam, approximate 60-second absorption claim, online launch first and future retail expansion. |
| contemporary-obgyn-livi-coverage | Contemporary OB/GYN coverage of Livi | Secondary clinical/trade coverage of Livi design, post-intercourse positioning, online-to-retail launch path, and category narrative. |
| market-us-global-tampon-2024 | Market.us global tampon market summary | Third-party market estimate: global tampon market at approximately USD 6.6B in 2024 and projected growth; used only as adjacent market-sizing input. |
| cmi-north-america-feminine-hygiene-2024 | Custom Market Insights North America feminine hygiene market summary | Third-party market estimate: North America feminine hygiene products market at approximately USD 8.76B in 2024; used only as broad adjacent category input. |
| us-census-age-sex-population | U.S. Census national population estimates by age and sex | Official population dataset reference for estimating target-user population ranges; customer-specific segmentation still requires separate market research. |